Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – Time to Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s share price gapped up before the market opened on Monday . The stock had previously closed at $14.56, but opened at $15.4168. Astellas Pharma shares last traded at $14.85, with a volume of 11,098 shares changing hands.

Analysts Set New Price Targets

Separately, Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy”.

Astellas Pharma Trading Up 0.1%

The firm has a market capitalization of $26.89 billion, a price-to-earnings ratio of 11.31 and a beta of 0.08. The company has a fifty day moving average price of $14.25 and a 200-day moving average price of $14.55. The company has a current ratio of 1.20, a quick ratio of 0.93 and a debt-to-equity ratio of 0.16.

About Astellas Pharma

Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops and commercializes prescription medicines for serious and unmet medical needs. Its research and commercial activities focus on areas including oncology, urology, immunology, neuromuscular diseases, ophthalmology and other specialty conditions.

The company’s portfolio includes treatments such as XTANDI for certain prostate cancers, XOSPATA for acute myeloid leukemia, MYRBETRIQ for overactive bladder and VEOZAH for menopausal hot flashes.